NEW YORK (GenomeWeb News) – Danaher today said that revenues in the fourth quarter rose nearly 6 percent year over year paced by its Life Sciences and Diagnostics segment.

For the three months ended Dec. 31, 2012, the company posted total revenues of $4.98 billion, up from $4.72 billion in the year-ago period, and beating the consensus Wall Street estimate of $4.81 billion.

Core revenues increased 3.5 percent year over year during the quarter, while acquisitions added 3 percent growth, and the impact of currency translation cut growth by 1 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.